US EditionPublished • loading... • Updated
MitoRx Therapeutics raises GBP 5.5 million pre-Series A round to advance a next generation obesity treatment
Summary by Harwell Campus
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MitoRx Therapeutics raises GBP 5.5 million pre-Series A round to advance a next generation obesity treatment
Back MitoRx Therapeutics raises GBP 5.5 million pre-Series A round to advance a next generation obesity treatment December 1, 2025 Share Tweet Life sciences and health, Science and innovation Harwell Campus based MitoRx Therapeutics Limited (MitoRx), a biotech company developing novel classes of mitochondrial-targeted agents targeting obesity, has announced a GBP 5.5 million (USD 7.2 million) pre-Series …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
